Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mymd Pharmaceuticals Inc MYMD

Healthcare
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro... see more

Recent & Breaking News (NDAQ:MYMD)

Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement

Business Wire November 12, 2020

Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results

GlobeNewswire August 27, 2020

Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire August 11, 2020

Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies

GlobeNewswire July 7, 2020

Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire May 18, 2020

Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire May 14, 2020

Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP

GlobeNewswire May 14, 2020

Here's How Akers Biosciences and Premas Biotech Plan To Knock Out COVID-19 Virus; Company Halfway Through Four Milestone Plan

Newsfile April 24, 2020

Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens

GlobeNewswire April 8, 2020

Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire April 7, 2020

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

GlobeNewswire April 6, 2020

Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate

GlobeNewswire March 24, 2020

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

GlobeNewswire March 24, 2020

Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

GlobeNewswire January 17, 2020

Akers BioSciences Regains Compliance with Nasdaq Listing Standards

GlobeNewswire December 11, 2019

Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia

Accesswire December 10, 2019

Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering

GlobeNewswire December 9, 2019

Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

GlobeNewswire December 6, 2019

Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering

GlobeNewswire December 5, 2019

Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry

GlobeNewswire December 5, 2019